Pessary

Cervical Cancer Drugs: Industry Trends and Opportunity Forecast, 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022

The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • North America is the largest region in the cervical cancer drugs market in 2021.
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.

Global Cervical Cancer Drugs Market (2021 to 2030) - Featuring Hetero, GlaxoSmithKline and Allergan Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021

The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.

Key Points: 
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.
  • For instance, companies introduced vaginal gels such as Cidofovir gel and 851B Gel into the market to treat cervical cancer.
  • In addition to the above mentioned gels, drugs such as ISA101, AGEN2034 and Z-100 are in pipeline and promise growth to the cervical cancer drugs market.

A New Self-use Innovative Treatment for Pelvic Organ Prolapse in Women (POP) Designed by ConTIPI Medical

Retrieved on: 
Monday, November 18, 2019

CAESAREA, Israel, Nov. 18, 2019 /PRNewswire/ -- ConTIPI Medical developscutting edge non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders.

Key Points: 
  • CAESAREA, Israel, Nov. 18, 2019 /PRNewswire/ -- ConTIPI Medical developscutting edge non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders.
  • The Company's current device is designed for the management of Pelvic Organ Prolapse (POP) in women and currently has 510(k) clearance for marketing in the United States, and a CE Mark for marketing in the EU.
  • ConTIPI Medical developed the ProVate Device for POP, designed to overcome many of the downsides of existing pessaries.
  • For more than 90% of women, complications associated with surgery were the key reasons for not being satisfied with the treatment.